Liver Cancer News
-
Only 51 percent of people in the U.S. who test positive for hepatitis C received the necessary follow- up to determine if they require medical care, according to the Centers for Disease Control and Prevention.
-
Achillion Pharmaceuticals Inc. said an experimental drug against hepatitis C suppressed the virus in 63 percent patients in a study.
-
Bristol-Myers Squibb Co., the New York drugmaker that gained 22 percent the past year, said its combination of three experimental medicines for hepatitis C successfully cleared the virus in 15 of 16 patients.
-
Sanofi, France’s biggest drugmaker, sees revenue growth opportunities from treatments for liver disease in China, home to half the world’s deaths related to the organ, Chief Executive Officer Chris Viehbacher said.
-
Exxon Mobil Corp. will appeal a $236 million New Hampshire verdict in a case over the use of the gasoline additive MTBE, after having gotten a much larger award in a similar dispute thrown out by a court in Maryland.
-
Exxon Mobil Corp. should pay New Hampshire $236 million in damages for contaminating its drinking water with the gasoline additive MTBE, the state’s lawyers told a jury that is set to begin deliberations today.
-
Bristol-Myers Squibb Co. said its experimental brivanib drug for liver cancer didn’t improve patient survival better than a placebo.
-
A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year, a study found.
-
Celsion Corp. plunged the most ever in New York trading after the company announced its experimental treatment for liver cancer failed in a study.
-
K. Anji Reddy, the founder of Dr. Reddy’s Laboratories Ltd., India’s second-largest drugmaker, died Friday after “ailing for some time,” the company said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page